La chaîne d'options affiche les données clés des options sur actions de Shattuck Labs à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Shattuck Labs..

Shattuck Labs (NASDAQ:STTK) Stock, Chaîne d'Options

SHATTUCK LABS INC

Shattuck Labs

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Shattuck Labs Inc

News

Press Releases

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Health Care

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Earnings

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Financing

Management

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

IRON

STTK

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Anixa Biosciences

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Atossa Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coya Therapeutics

CervoMed

EXoZymes

Fortress Biotech

HilleVax

Immunic

Kala Bio

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MEI Pharma

Macrogenics

Ovid Therapeutics

PMV Pharma

Pelthos Therapeutics

Quince Therapeutics

Surrozen

TScan Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Wedbush

Leerink Partners

Citigroup

Comments

Shattuck Labs

Shattuck Labs (STTK) Options

Shattuck Labs (NASDAQ:STTK) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL